Kronos Bio has announced the appointment of Deborah Knobelman as president and interim chief executive officer, effective from 3 December 2024. Dr Knobelman will also become principal executive ...

Kronos Bio, Inc. has entered into a Transition Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd to terminate their previous Collaboration and License Agreement. As part of the agreement ...

Shares of cancer therapy developer Kronos Bio Inc. ($KRON) surged over 13% to hit their highest level since Nov. 6, with trading volume spiking more than six times ...